| Predicted Trait | |
| Reported Trait | Estrogen receptor positive breast cancer |
| Mapped Trait(s) | estrogen-receptor positive breast cancer (EFO_1000649) |
| Score Construction | |
| PGS Name | PRS179_ERpos |
| Development Method | |
| Name | Genome-wide significant variants |
| Parameters | NR |
| Variants | |
| Original Genome Build | GRCh37 |
| Number of Variants | 179 |
| Effect Weight Type | log(OR) |
| PGS Source | |
| PGS Catalog Publication (PGP) ID | PGP000179 |
| Citation (link to publication) | Du Z et al. J Natl Cancer Inst (2021) |
| Ancestry Distribution | |
| Source of Variant Associations (GWAS) | European: 100% 227,101 individuals (100%) |
| PGS Evaluation | |
| Study Identifiers | Sample Numbers | Sample Ancestry | Cohort(s) |
|---|---|---|---|
GWAS Catalog: GCST005077 Europe PMC: 29058716 |
87,827 individuals | European | 127 cohorts
|
GWAS Catalog: GCST004988 Europe PMC: 29059683 |
139,274 individuals | European | NR |
|
PGS Performance Metric ID (PPM) |
PGS Sample Set ID (PSS) |
Performance Source | Trait |
PGS Effect Sizes (per SD change) |
Classification Metrics | Other Metrics | Covariates Included in the Model |
PGS Performance: Other Relevant Information |
|---|---|---|---|---|---|---|---|---|
| PPM002007 | PSS000995| Multi-ancestry (excluding European)| 19,434 individuals |
PGP000179 | Du Z et al. J Natl Cancer Inst (2021) |
Reported Trait: Estrogen-receptor positive breast cancer | OR: 1.33 [1.27, 1.38] | — | — | Age, study, PCs(1-10) | Only 163 of the original 179 SNPs were avaialble in all consortia (imputation score r^2 < 0.8).For missing variants (not genotyped or imputed) in one study, each individual in that study was assigned the expected dosage derived from the remainder of studies |
| PPM002008 | PSS000995| Multi-ancestry (excluding European)| 19,434 individuals |
PGP000179 | Du Z et al. J Natl Cancer Inst (2021) |
Reported Trait: Estrogen-receptor positive breast cancer | — | AUROC: 0.576 [0.566, 0.585] | — | Study, PCs(1-10) | Only 163 of the original 179 SNPs were avaialble in all consortia (imputation score r^2 < 0.8).For missing variants (not genotyped or imputed) in one study, each individual in that study was assigned the expected dosage derived from the remainder of studies |
|
PGS Sample Set ID (PSS) |
Phenotype Definitions and Methods | Participant Follow-up Time | Sample Numbers | Age of Study Participants | Sample Ancestry | Additional Ancestry Description | Cohort(s) | Additional Sample/Cohort Information |
|---|---|---|---|---|---|---|---|---|
| PSS000995 | Cases are women with breast cancer. Of the 3928 breast cancer cases, 1533 were ER-positive and 987 were ER-negative. | — | [ ,
0.0 % Male samples |
Mean = 47.71 years | African American or Afro-Caribbean, Sub-Saharan African, African unspecified | — | 15 cohorts
|
All cohorts part of The GAME-ON OncoArray Consortium or The GWAS of Breast Cancer in the African Diaspora Consortium (ROOT) |
| PSS000995 | Cases are women with breast cancer. Of the 899 breast cancer cases, 296 were ER-positive and 277 were ER-negative. | — | [ ,
0.0 % Male samples |
— | Sub-Saharan African | — | GBHS | — |
| PSS000995 | Cases are women with breast cancer. Of the 4414 breast cancer cases, 2470 were ER-positive and 1372 were ER-negative. | — | [ ,
0.0 % Male samples |
— | African American or Afro-Caribbean | — | 10 cohorts
|
All cohorts part of African American Breast Cancer (AABC) consortium and/or The African American Breast Cancer Epidemiology and Risk (AMBER)consortium. |